| Name | Title | Contact Details |
|---|
The National Quality Forum (NQF) is the nation`s resource for healthcare quality measurement and improvement. NQF is an independent, not-for-profit, membership-based organization that brings healthcare stakeholders together to recommend quality measures and improvement strategies that reduce costs and help patients get better care. NQF`s membership consists of more than 400 organizations that represent physicians, nurses, hospitals, healthcare systems, patients, families, health plans, employers, and others committed to healthcare quality. Through its multistakeholder membership, NQF facilitates an open and thorough dialogue on healthcare measurement and improvement, and leads national collaboration to improve health and healthcare quality for all Americans.
SCP Health (SCP) is a clinical company. At our core we work to bring hospitals and healers together in the pursuit of clinical effectiveness. With a portfolio of over 8 million patients, 7500 providers, 30 states, and 400 healthcare facilities, SCP Health is a leader in clinical practice management spanning the entire continuum of care, including emergency medicine, hospital medicine, wellness, telemedicine, intensive care, and ambulatory care. Whether you`re a resident, nurse practitioner, physician assistant, physician, or medical director looking for a clinical career or a professional interested in opportunities at one of our corporate locations, we can find you a position that fits you professionally and personally.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Pacific Hospitalist Associates is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
TrestleTree is a Springdale, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.